Treatment with lamivudine, zidovudine, or both in hiv-positive patients with 200 to 500 cd4+ cells per cubic millimeter

New England Journal of Medicine

Volumn 333, Issue 25, 1995, Pages 1662-1669

  Eron, Joseph J ^a   Benoit, Sharon L ^a   Jemsek, Joseph ^a   Macarthur, Rodger D ^a   Santana, Jorge ^a   Quinn, Joseph B ^a   Kuritzkes, Daniel R ^a   Fallon, Mary Ann ^a   Rubin, Marc ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0029563673     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512213332502     Document Type: Article

References (45)

1. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993; 270: 2583-2589
2. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881
3. Ioannidis JPA, Cappelleri JC, Lau J, Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med 1995; 122: 856-866
4. Larder BA, Darby G, Richman DD HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-1734
5. Richman DD, Grimes JM, Lagakos SW Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3: 743-746
6. Caliendo AM, Hirsch MS Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994; 18: 516-524 [Erratum, Clin Infect Dis 1994;19:379.]
7. Collier AC, Coombs RW, Fischl MA, Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786-793
8. Yarchoan R, Lietzau JA, Nguyen B-Y, A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169: 9-17 [Erratum, J Infect Dis 1994;170:260.]
9. Fiscus SA, DeGruttola V, Gupta P, Human immunodeficiency virus type I quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995; 171: 305-311
10. Pantaleo G, Graziosi C, Demarest JF, HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358
11. Embretson J, Zupancic M, Ribas JL, Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362
12. Piatak M Jr, Saag MS, Yang LC, High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-1754
13. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
14. Wei X, Ghosh SK, Taylor ME, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122
15. Schinazi RF, Chu CK, Peck A, Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 1992; 36: 672-676
16. Coates JAV, Cammack N, Jenkinson HJ, (-)-2'-Deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36: 733-739
17. Coates JAV, Cammack N, Jenkinson HJ, The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36: 2025-2025
18. Viner KC, Cammack N, Coates JAV, et al. Levoenantiomeric 2'deoxy-3'-thiacytidine (3TC) in combination with AZT synergistically inhibits clinical isolates of HIV-1. In: Abstracts of the Ninth International Conference on AIDS/Fourth STD World Congress, Berlin, Germany, June 6– 11, 1993. London: Wellcome Foundation, 1993:236. abstract.
19. Tisdale M, Kemp SD, Parry NR, Larder BA Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 5653-5656
20. Schinazi RF, Lloyd RM Jr, Nguyen M-H, Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875-881
21. Boucher CA, Cammack N, Schipper P, High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234
22. van Leeuwen R, Lange JM, Hussey EK, The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992; 6: 1471-1475
23. van Leeuwen R, Katlama C, Kitchen V, Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995; 171: 1166-1171
24. Fischl MA, Stanley K, Collier AC, Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32
25. Dawson JD Comparing treatment groups on the basis of slopes, areas under-the-curve, and other summary measures. Drug Inf J 1994; 28: 723-732
26. van Elteren P On the combination of independent two sample tests of Wilcoxon. Bull Inst Int Stat 1960; 37: 351-361
27. Wei LJ, Johnson WE Combining dependent tests with incomplete repeated measurements. Biometrika 1985; 72: 359-364
28. Mellors JW, Kingsley LA, Rinaldo CR Jr, Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579
29. Henrard DR, Phillips JF, Muenz LR, Natural history of HIV-1 cell-free viremia. JAMA 1995; 274: 554-558
30. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte count relative to treatment and progression to AIDS. N Engl J Med (in press).
31. Hooper C, Welles S, D'Aquila RT, et al. HIV-1 RNA level in plasma and association with disease progression, zidovudine sensitivity phenotype and genotype, syncytium-inducing phenotype, CD4+ cell count and clinical diagnosis of AIDS. Presented at the Third International Workshop for HIV Drug Resistance, Kauai, Hawaii, August 2– 5, 1994:67. abstract.
32. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic capacity of plasma HIV-1 RNA copy number in ACTG 116A. In: Abstracts of the Second National Conference on Human Retroviruses, Washington, D.C., January 29– February 2, 1995. Washington, D.C.: American Society of Microbiology, 1995:96. abstract.
33. Fischl MA, Richman DD, Grieco MH, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-191
34. Volberding PA, Lagakos SW, Koch MA, Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-949
35. Dolin R, Amato DA, Fischl MA, Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med 1995; 155: 961-974
36. Pavia AT, Gathe J, BMS-019 Study Group Investigators. Clinical efficacy of stavudine (d4T, Zerit) compared to zidovudine (ZDV, Retrovir) in ZDV-pretreated HIV positive patients. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17– 20, 1995. Washington, D.C.: American Society of Microbiology, 1995:235. abstract.
37. Mathez D, Schinazi RF, Liotta DC, Leibowitch J Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993; 37: 2206-2211
38. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91: 2326-2333
39. Katlama C, European Lamivudine HIV Working Group. Combination 3TC/ZDV vs ZDV monotherapy in ZDV naive HIV-1 positive patients with a CD4 of 100-400 cells/mm3. In: Abstracts of the Second National Conference on Human Retroviruses, Washington, D.C., January 29– February 2, 1995. Washington, D.C.: American Society of Microbiology, 1995:173. abstract.
40. Larder BA, Kemp SD, Harrigan PR Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699
41. Schuurman R, Nijhuis M, van Leeuwen R, Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411-1419
42. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA Crystal structure at 3.5 Ã… resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790
43. Larder BA, Kemp SD, Purifoy DJM Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A 1989; 86: 4803-4807
44. Boyer PL, Ferris AL, Hughes SH Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J Virol 1992; 66: 1031-1039
45. Coffin JM HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-489